30 Day Trial

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

COVID-19 Impact: Procedure Deferrals Will Lead to Revenue Declines

After consulting with a host of industry veterans and observers, our guidance recommends that you expect and plan for business disruptions and revenue declines across the board—all companies, all market segments.

In the same breath, we’re confident that the orthopedic market will recover due to demographics and the lasting economic need to keep us all active and productive. The majority of procedures that are being delayed will remain in queue, and new patients will continue to feed a robust orthopedic pipeline.

7 Digital Tools We Wanted to See at AAOS

Robotic systems would have undoubtedly received major play at the Annual Meeting. Numerous technologies from startup to mid-sized companies would have been on display in the exhibit hall—a departure from just a few years ago, when mainly the larger players were talking about these tools. These technologies, primarily in joint replacement and spine, span the continuum of care. Some are being developed and launched alongside dedicated implants and instruments, while others are standalone.

Along with a description of the technology, we pulled together recent strategic activity and development milestones to provide greater insight.

Renovos to Develop Next-Gen Technology to “Tame” BMP-2 Diffusion

Regenerative medicine is an emerging market with solutions to not only heal but also grow tissue and bone. Trauma and disease that damage tissue and bones leave a lasting impact that traditional repair methods have failed to address in the long-term. Further, with life expectancy increases and the prevalence of musculoskeletal trauma in active young people, the need is higher than ever for effective, long-term treatments. 

Renovos is addressing the issue of biological molecule diffusion through a synthetic nanoclay gel technology platform called Renovite. The injectable material stimulates the patient’s stem cells to generate new tissue. With time, it is entirely replaced by the newly-formed tissue at the exact location it was applied.

Studies Shed Light on Late-Onset Infection

While the spine industry has focused on 3D printed cages, enabling technology and minimally invasive surgery, it has forgotten a critical priority: infection prevention, says Aakash Agarwal, Ph.D., Director of Research at Spinal Balance. He argues that the millions of reprocessed and exposed orthopedic devices in the field should be a significant focus for the industry.

“Every upcoming technology in the field of orthopedics focuses on precision and efficacy, with the intention to boost performance (healing) and safety,” he said. “Avoiding reprocessing and intraoperative exposure is the most obvious (and also most neglected) safety measure in the orthopedic industry. Fixing this problem will be a major leap toward patient safety.”

We asked Dr. Agarwal four questions about what his recent research found and ways to handle infections.

Orthobiologics Face Pressure from Lack of Clinical Evidence

In the race to capitalize on patient-driven interest in stem cells, biologic solutions and “regeneration” of a more vital, healthy and functional body, there has been an explosion of offerings that lack scientific controls, validity and meaningful evidence.

The opportunistic avarice of companies and physicians in response to patient demand has led to mercenary behavior that has begun to sully the field’s reputation. There are those who believe, however, that new regulatory guardrails, and a return to conscientious management of our precious healthcare resources, will swing the pendulum back to a state of more principled product promotion and patient care.

Page Navigation